Science Corporation

Science Corporation specializes in medical technology innovations, particularly neural engineering solutions aimed at enhancing the quality of life for patients with neurological conditions. Based in California, US, Science Corporation develops advanced medical technologies, focusing on neural engineering solutions. In March 2026, Science Corporation raised USD 230 million in series C funding led by Lightspeed Venture Partners, with participation from Khosla Ventures, Y Combinator, Quiet Capital, and In-Q-Tel. The series C funding values Science Corporation at USD 1.

5 billion post-money. Science Corporation is dedicated to advancing medical technologies, primarily focusing on neural engineering solutions designed to restore quality of life to individuals with debilitating conditions. The company's core product offerings include biohybrid neural interfaces, neural probes, and a fully wireless photovoltaic stimulation array, which facilitate communication between living neurons and electronic devices. These technologies aim to address conditions such as macular degeneration, retinitis pigmentosa, and Stargardt disease, enhancing vision restoration for affected patients.

Science Corporation's products are primarily sold in North America and Europe, targeting healthcare providers, research institutions, and clinical settings where innovative therapeutic solutions are required for neurological disorders. Science Corporation operates on a direct-to-consumer and B2B transaction structure, providing advanced medical technologies primarily to healthcare organizations and research facilities. The company generates revenue through the sale of its specialized products, which may include flagship offerings such as the PRIMA device and the SciFi neural probe. Transactions are typically structured around purchasing agreements, where clients procure the technology for research or clinical application.

The pricing plans are tailored to the specific needs of the institutions, reflecting the complexity and cutting-edge nature of the technologies employed. Revenue is driven by the demand from healthcare providers and the growing need for innovative solutions in neural engineering, leading to substantial investment in research and development initiatives. The company will use the March 2026 funding to accelerate PRIMA BCI commercialization and expand clinical trials for additional eye diseases like Stargardt disease.